Sign in
Taking peoplePhase 2

Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

Key facts

Who runs it
Victoria Biomedical Research Institute
Where
Kenya1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
1,116 people, planned
Started
20 Jan 2026
Expected to end
30 Jun 2027
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Artemether lumefantrine tablets
  • Artemether Lumefantrine and Imatinib Mesylate
Record updated
29 June 2026

Who can take part

Age
1 year to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (26)Hide the full registry criteria

Who can take part

  • For Part 1 and 2 of the study design, all individuals must meet all the inclusion criteria below:
  • Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with a parasite density of >= 5000 parasites/μl
  • Adult male, age 18-55 years old or adult female, age 18-55 years that are post-menopausal, or test negative on a pregnancy test and will be on active birth control through to the end of the follow up period
  • Provision of informed consent and agrees to hospital admission for 48-72hrs
  • Good health condition other than malaria
  • The patient has not taken anti-malarial drugs in the past 4 weeks; For Part 3 of the trial, all individuals must meet all the inclusion criteria below:
  • Patients diagnosed with symptomatic mild to moderate P. falciparum malaria and a parasite density of >= 5000 parasites/μl
  • Age 12 months to below 18 years
  • Presented by parent or legally accepted representative (LAR) who has consented to the participation of the child in the trial and agrees to hospital admission for 48-72hrs
  • Hb levels > 5mg/dL
  • Child has not taken anti-malarial drugs in the past 6 weeks

Who cannot take part

  • Concomitant infection by plasmodium species other than P. falciparum
  • Concomitant use of medicines, including:; medicines used to treat high cholesterol (such as atorvastatin, lovastatin, simvastatin); medicines used to treat hypertension and heart problems (such as diltiazem, nifedipine, nitrendipine, verapamil, felodipine, amlodipine); medicine used to treat HIV (antiretroviral medicines) including protease inhibitors (such as amprenavir, atazanavir, indinavir, nelfinavir, ritonavir), non-nucleoside reverse transcriptase inhibitors (such as efavirenz, nevirapine); medicines used to treat microbial infections (such as telithromycin, rifampicin, dapsone); medicines used to help you fall asleep: benzodiazepines (such as midazolam, triazolam, diazepam, alprazolam), zaleplon, zolpidem; medicines used to prevent/treat epileptic seizures including barbiturates (such as phenobarbital), carbamazepine or phenytoin; medicines used after organ transplantation and in autoimmune diseases (such as cyclosporin, tacrolimus); nefazodone (used to treat depression); aprepitant (used to treat nausea)
  • Symptoms and signs of severe or complicated malaria including:; significant confusion or impaired consciousness (including unarousable coma); multiple convulsions (more than two episodes within 24 hours),; respiratory distress; circulatory collapse (systolic blood pressure <80mm Hg with evidence of impaired perfusion); clinical jaundice plus evidence of other vital organ dysfunction; simultaneous infection of unrelated origin
  • Other neurological or psychiatric symptoms or disorders
  • Abnormal bleeding
  • Resting heart rate lower than 55 or higher than 100 bpm
  • History of cardiac disease
  • Symptoms and signs of infection such as pneumonia, dengue fever, and other viral or bacterial infection
  • Patients with symptoms of gastrointestinal infections or any sign of malabsorption that may interfere with drug absorption
  • Signs, symptoms and laboratory results of impairment of vital organs such as liver, lungs, kidney and cardiovascular system
  • Abnormal blood chemistry:; hemoglobin < 9.0 g/dL in adults or < 5.0 g/dL in children 12 months-18 years; WBC not in the range of 4800-10,000/mm3; RBC if < 4.0x106/ mm3; Platelet < 1.3x105/ mm3; ALAT not in the normal range (4 to 36 U / l); ASAT not in the normal range (8 to 33 U / l); Total bilirubin 0.1 to 1.2 mg / 100 ml; Serum protein if < 5.5 g/dL
  • Prospective study participant, LAR and/or impartial witness (where applicable) declines to provide informed consent
  • Parasite density > 200,000 parasites /μl
  • In the case of female participants: currently pregnant or lactating
  • Inability to attend/meet study staff on follow up visits

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Malaria

This trial is currently available in Kenya.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa

The 5 groups in the trial

  • Artemether Lumefantrine AloneExisting treatment, for comparison

    Standard 3-day course. Used as control in all parts.

    Treatment: Artemether lumefantrine tablets

  • Artemether Lumefantrine and Imatinib 400mg Twice Daily (3 days)Treatment being tested

    3-day course with imatinib 400mg twice daily.

    Treatment: Artemether Lumefantrine and Imatinib Mesylate

  • Artemether Lumefantrine and Imatinib (Optimal Dose, 3 days)Treatment being tested

    3-day course with optimal dose determined from Part 1.

    Treatment: Artemether Lumefantrine and Imatinib Mesylate

  • Artemether Lumefantrine and Imatinib (Optimal Dose, 2 days)Treatment being tested

    2-day imatinib course (optimal dose) with 3-day AL.

    Treatment: Artemether Lumefantrine and Imatinib Mesylate

  • Pediatric: Artemether Lumefantrine and Imatinib (Weight-based)Treatment being tested

    Weight-based imatinib (340 or 260 mg/m²/day, max 600mg) plus weight-based AL for 3 days.

    Treatment: Artemether Lumefantrine and Imatinib Mesylate

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating the Safety and Efficacy of Imatinib in Combination With Artemether and Lumefantrine for Treatment of Uncomplicated Malaria
Criteria questions
Built from NCT07559370, who can take part
Record updated
29 June 2026